Back to Results
First PageMeta Content
Health / Congenital muscular dystrophy / European Medicines Agency / Omigapil / Medicine / Neurology / Muscular dystrophy / Integrins / Laminin


6 April 2011 EMA/COMP[removed]Rev.1 Committee for Orphan Medicinal Products
Add to Reading List

Document Date: 2013-07-21 04:59:00

Open Document

File Size: 122,69 KB

Share Result on Facebook

City

London / /

Company

Santhera Pharmaceuticals (Deutschland) GmbH / /

Continent

Europe / /

Country

Germany / Norway / Iceland / United Kingdom / /

/

Facility

Canary Wharf / /

IndustryTerm

orphan medicinal product / orphan medicinal products / /

MedicalCondition

rare diseases / Mental retardation / progressive muscle weakness / disease / respiratory failure / CMD / hereditary disorders / joint deformities / congenital muscular dystrophy / deficiency / contractures / Congenital muscular dystrophies / scoliosis / /

Organization

European Medicines Agency / Committee for Orphan Medicinal Products Public / European Commission / European Union / European Organisation for Rare Diseases / E-mail info@ema.europa.eu Website www.ema.europa.eu An / Committee for Orphan Medicinal Products / /

/

Technology

alpha / av / /

URL

www.ema.europa.eu / /

SocialTag